Abstract: A method for treating a disease or disorder characterized by amyloid deposit of A-beta comprising administering to the subject a therapeutically effective amount of an antibody that binds specifically to RAGE and inhibits the binding of a RAGE binding partner.

Abstract: The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (A?). Preferred agents include antibodies, e.g., humanized antibodies specific for A?.

Abstract: Novel proteins which bind human ?-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided. Transgenic animals and knockout animals are also provided.

Abstract: In various aspects, the present invention provides methods and kits for predicting the therapeutic efficacy of an immunological reagent, identifying an immunological reagent having therapeutic efficacy, or both, for the treatment of an amyloidogenic disorder by comparing the amount of A? monomer in an A? preparation which binds to the immunological reagent to an amount of one or more A? oligomers in the A? preparation which bind to the immunological reagent to determine a relative bound amount, and predicting the efficacy of the immunological reagent, identifying an immunological reagent having therapeutic efficacy, or both, for the treatment of an amyloidogenic disorder based at least on the relative bound amount.

Abstract: The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (A?). Preferred agents include antibodies, e.g., humanized antibodies specific for A?.

Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.

Abstract: The invention provides methods for determining effective immunotherapeutic agents which may be used for the treatment of cognitive disorders.

Abstract: Use of animal models of neurodegenerative disorders for establishment of preclinical diagnostic and therapeutic indices, and for screening methods to identify effective preclinical therapies.

Abstract: Novel proteins which bind human ?-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided. Transgenic animals and knockout animals are also provided.

Abstract: Novel proteins which bind human ?-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided. Transgenic animals and knockout animals are also provided.